News Redwood Pharma AB

Equities

REDW

SE0021512134

Delayed Nasdaq Stockholm Other stock markets 06:19:17 2024-05-24 am EDT			5-day change	1st Jan Change
0.696 ^SEK	0.00%		-32.75%	-85.19%

May. 08	Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	CI
May. 07	Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Redwood Pharma provides an update on the company's future	May. 23	AQ
Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle	May. 08	AQ
Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	May. 08	CI
Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements	May. 07	AQ
Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	May. 07	CI
Redwood Pharma's board subscribes to units in the ongoing new issue	May. 06	AQ
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle	Feb. 28	AQ
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Redwood Pharma's CEO Martin Vidaeus in year-end interview	Dec. 20	AQ
Redwood Pharma to participate in the JP Morgan Healthcare Conference	Dec. 19	AQ
Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Redwood Pharma to participate in the NLS Days partner conference in Copenhagen	Nov. 22	AQ
Redwood Pharma to participate in the BIO-Europe partnering conference in Munich	23-10-19	AQ
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Redwood Pharma presents positive results from a clinical study with RP501 against dry eye	23-05-31	AQ
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	23-05-31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye	23-03-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Redwood Pharma AB

Equities

REDW

SE0021512134

Summary

Filters